FMFritz Melchers

Fritz Melchers

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Fritz Melchers has a total of 24 co-authors. Here are the top co-authors by number of shared publications:

  • Katharina Seiler

    Max Planck Institute for Infection Biology, Lymphocyte Development Group, Berlin, Germany

    4 shared publications
  • Motokazu Tsuneto

    Max Planck Institute for Infection Biology, Charitéplatz 1, 10117 Berlin, Germany

    4 shared publications
  • Andreas Grützkau

    German Rheumatism Research Center (DRFZ), a Leibniz Institute, Berlin, Germany

    3 shared publications
  • Anja Erika Hauser

    German Rheumatology Research Center (DRFZ) Berlin, a Leibniz Institute, Berlin, Germany

    3 shared publications
  • Corinne Bouquet

    Max Planck Institute for Infection Biology, Lymphocyte Development Group, Berlin, Germany

    3 shared publications
  • Ekaterina Kajikhina

    Max Planck Institute for Infection Biology, Lymphocyte Development Group, Berlin, Germany

    3 shared publications

Latest Publications

  • Remembering antibodies coming of age

    by Fritz Melchers

    Fifty years ago, Norbert Hilschmann discovered that antibodies have variable immunoglobulin domains to bind antigens, and constant domains to carry out effector functions in the immune system. Just as this happened, the author of this perspective entered the field of immunology. Ten years later, the genetic basis of antibody variability was discovered by Susumu Tonegawa and his colleagues at the Basel Institute for Immunology, where the author had become a scientific member. At the same time, Georges Köhler, a former graduate student of the author's at the Basel Institute, invented with Cesar Milstein at the Laboratory of Molecular Biology in Cambridge, England, the method to produce monoclonal antibodies. The author describes here his memories connected to these three monumental, paradigm-changing discoveries, which he observed in close proximity.


    • 12 October 2015
      • Vol. 33, S91-3

    Environments of hematopoiesis and B-lymphopoiesis in foetal liver.

    by Katja Kajikhina, Motokazu Tsuneto, Fritz Melchers

    In human and murine embryonic development, haematopoiesis and B-lymphopoiesis show stepwise differentiation from pluripotent haematopoietic stem cells and multipotent progenitors, over lineage-restricted lymphoid and myeloid progenitors to B-lineage committed precursors and finally differentiated pro/preB cells. This wave of differentiation is spatially and temporally organised by the surrounding, mostly non-haematopoietic cell niches. We review here recent developments and our current contributions on the research on blood cell development.


  • Open Access

    Chemokine polyreactivity of IL7Rα+CSF-1R+ lympho-myeloid progenitors in the developing fetal liver

    by Katja Kajikhina, Fritz Melchers, Motokazu Tsuneto

    In murine ontogeny, fetal liver is the major hemato- and B-lymphopoietic site until birth. Hematopoiesis develops in largely non-hematopoietic niches, which provide contacts, chemokines and cytokines that induce migration, residence, proliferation and differentiation of progenitors. Within early multipotent progenitors an IL7Rα+CSF-1R+ subset expressed a mixture of lymphoid- and myeloid-specific genes and differentiated to lymphoid and myeloid lineages in vitro. By contrast, IL7Rα+ cells were lymphoid-committed, and CSF-1R+ cells were erythro-myeloid-restricted. To respond to a multitude of chemokines single biphenotypic cells expressed CXCR4 and as many as five other chemokine receptors. The monopotent IL7Rα+ and CSF-1R+progenitors all expressed CXCR4, and mutually exclusive, more restricted sets of the analysed five chemokine receptors. This study proposes that chemokine polyreactive, cytokine-bipotent and monopotent progenitors transmigrate through LYVE-1high endothelium, attracted by selected chemokines, and reach the IL7- and CSF-1-producing ALCAMhigh mesenchymal niche, attracted by other sets of chemokines, to differentiate to B-lymphoid respectively myeloid cells.


  • Open Access

    Checkpoints that control B cell development

    by Fritz Melchers

    B cells differentiate from pluripotent hematopoietic stem cells (pHSCs) in a series of distinct stages. During early embryonic development, pHSCs migrate into the fetal liver, where they develop and mature to B cells in a transient wave, which preferentially populates epithelia and lung as well as gut-associated lymphoid tissues. This is followed by continuous B cell development throughout life in the bone marrow to immature B cells that migrate to secondary lymphoid tissues, where they mature. At early stages of development, before B cell maturation, the gene loci encoding the heavy and light chains of immunoglobulin that determine the B cell receptor composition undergo stepwise rearrangements of variable region-encoding gene segments. Throughout life, these gene rearrangements continuously generate B cell repertoires capable of recognizing a plethora of self-antigens and non–self-antigens. The microenvironment in which these B cell repertoires develop provide signaling molecules that play critical roles in promoting gene rearrangements, proliferation, survival, or apoptosis, and that help to distinguish self-reactive from non–self-reactive B cells at four distinct checkpoints. This refinement of the B cell repertoire directly contributes to immunity, and defects in the process contribute to autoimmune disease.


  • Reprint of: Environments of B cell development

    by Motokazu Tsuneto, Ekaterina Kajikhina, Katharina Seiler, Andreas Reimer, Julia Tornack, Corinne Bouquet, Szandor Simmons, Marko Knoll, Ingrid Wolf, Koji Tokoyoda, et al.


  • Environments of B cell development

    by Motokazu Tsuneto, Ekaterina Kajikhina, Katharina Seiler, Andreas Reimer, Julia Tornack, Corinne Bouquet, Szandor Simmons, Marko Knoll, Ingrid Wolf, Koji Tokoyoda, et al.


  • Open Access

    Ectopic Runx1 Expression Rescues Tal-1-Deficiency in the Generation of Primitive and Definitive Hematopoiesis

    by Julia Tornack, Katharina Seiler, Andreas Grützkau, Joachim R. Grün, Masafumi Onodera, Fritz Melchers, Motokazu Tsuneto

    The transcription factors SCL/Tal-1 and AML1/Runx1 control the generation of pluripotent hematopoietic stem cells (pHSC) and, thereby, primitive and definitive hematopoiesis, during embryonic development of the mouse from mesoderm. Thus, Runx1-deficient mice generate primitive, but not definitive hematopoiesis, while Tal-1-deficient mice are completely defective. Primitive as well as definitive hematopoiesis can be developed “in vitro” from embryonic stem cells (ESC). We show that wild type, as well as Tal-1−/− and Runx1−/− ESCs, induced to differentiation, all expand within 5 days to comparable numbers of Flk1+ mesodermal cells. While wild type ESCs further differentiate to primitive and definitive erythrocytes, to c-fms+Gr1+Mac1+ myeloid cells, and to B220+CD19+ B- and CD4+/CD8+ T-lymphoid cells, Runx1−/− ESCs, as expected, only develop primitive erythrocytes, and Tal-1−/− ESCs do not generate any hematopoietic cells. Retroviral transduction with Runx1 of Runx1−/− ESCs, differentiated for 4 days to mesoderm, rescues definitive erythropoiesis, myelopoiesis and lymphopoiesis, though only with 1–10% of the efficiencies of wild type ESC hematopoiesis. Surprisingly, Tal-1−/− ESCs can also be rescued at comparably low efficiencies to primitive and definitive erythropoiesis, and to myelopoiesis and lymphopoiesis by retroviral transduction with Runx1. These results suggest that Tal-1 expression is needed to express Runx1 in mesoderm, and that ectopic expression of Runx1 in mesoderm is sufficient to induce primitive as well as definitive hematopoiesis in the absence of Tal-1. Retroviral transduction of “in vitro” differentiating Tal-1−/− and Runx1−/− ESCs should be a useful experimental tool to probe selected genes for activities in the generation of hematopoietic progenitors “in vitro”, and to assess the potential transforming activities in hematopoiesis of mutant forms of Tal-1 and Runx1 from acute myeloid leukemia and related tumors.


  • B-Cell Progenitors and Precursors Change Their Microenvironment in Fetal Liver During Early Development

    by Motokazu Tsuneto, Koji Tokoyoda, Ekaterina Kajikhina, Anja E. Hauser, Takahiro Hara, Shizue Tani-Ichi, Koichi Ikuta, Fritz Melchers

    The microenvironments, in which B lymphocytes develop in fetal liver, are largely still unknown. Among the nonhematopoietic cells, we have identified and FACS‐separated two subpopulations, CD45−TER119−VCAM‐1+ cells that are either CD105highLYVE‐1high or CD105lowALCAMhigh. Immunohistochemical analyses find three of four c‐Kit+IL‐7Rα+B220lowCD19−SLC− B progenitors in contact with vascular endothelial‐type LYVE‐1high cells on embryonic day 13.5. One day later c‐Kit+IL‐7Rα+ cells develop to CD19− and +, SLC‐expressing, DHJH‐rearranged pre/pro and pro/preB‐I cells. Less than 10% are still in contact with LYVE‐1high cells, but half of them are now in contact with mesenchymally derived ALCAMhigh liver cells. All of these ALCAMhigh cells, but not the LYVE‐1high cells produce IL‐7 and CXCL12, while both produce CXCL10. Progenitors and pro/preB‐I cells are chemoattracted in vitro toward CXCL10 and 12, suggesting that lymphoid progenitors with Ig gene loci in germline configuration enter the developing fetal liver at E13.5 from vascular endothelium, attracted by CXCL10, and then migrate within a day to an ALCAMhigh liver cell microenvironment, differentiating to DHJH‐rearranging, surrogate light chain‐expressing pre/proB and pro/preB‐I cells, attracted by CXCL10 and 12. Between E15.5 and E16.5 preB‐I cells expand 10‐fold in continued contact with ALCAMhigh cells and begin VH‐ to DHJH‐rearrangements in further differentiated c‐Kit−IL‐7Rα− preBII cells. STEM Cells 2013;31:2800–2812


  • Open Access

    Pim1 and Myc reversibly transform murine precursor B lymphocytes but not mature B lymphocytes

    by Corinne Bouquet, Fritz Melchers

    The proto‐oncogenes Myc and Pim1, which are deregulated in many types of cancers, are known to cooperate in B lymphoma development. Here we show that overexpression of retrovirally transduced, doxycycline‐inducible Myc alone in IL‐7‐deprived, growth‐arrested pre‐B cells enhanced cell cycle entry without impairing apoptosis. Overexpression of Pim1 decreased apoptosis, but had no effect on cell cycle entry. Co‐expression of Pim1 and Myc inhibited apoptosis and led to IL‐7‐independent proliferation of the transduced pre‐B cells in vitro, while blocking their differentiation to IgM+ immature cells. Transplantation of Pim1/Myc overexpressing pre‐BI cells into B‐cell‐deficient mice expanded the pre‐B‐cell compartments up to 100‐fold within 4–8 weeks. Transformation remained dependent on the expression of both oncogenes, as removal of doxycycline in vitro and in vivo terminated proliferation and induced differentiation to IgM+ B cells. In contrast, Pim1/Myc‐transduced mature B cells that developed from the oncogene‐transduced pre‐BI cells in the absence of oncogene overexpression in vivo were not capable of long‐term proliferation after induction of Pim and Myc overexpression, neither in vivo nor in vitro, neither with nor without stimulation by polyclonal activators.


  • Open Access

    Experimental Limitations Using Reprogrammed Cells for Hematopoietic Differentiation

    by Katharina Seiler, Motokazu Tsuneto, Fritz Melchers

    We review here our experiences with the in vitro reprogramming of somatic cells to induced pluripotent stem cells (iPSC) and subsequent in vitro development of hematopoietic cells from these iPSC and from embryonic stem cells (ESC). While, in principle, the in vitro reprogramming and subsequent differentiation can generate hematopoietic cell from any somatic cells, it is evident that many of the steps in this process need to be significantly improved before it can be applied to human cells and used in clinical settings of hematopoietic stem cell (HSC) transplantations.